List of Excipients in Branded Drug PALONOSETRON HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	CITRIC ACID MONOHYDRATE
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	EDETATE DISODIUM
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	MANNITOL
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	SODIUM CITRATE

Generic Drugs Containing PALONOSETRON HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hospira Inc	palonosetron hydrochloride	0409-2503	CITRIC ACID MONOHYDRATE
Hospira Inc	palonosetron hydrochloride	0409-2503	EDETATE DISODIUM
Hospira Inc	palonosetron hydrochloride	0409-2503	HYDROCHLORIC ACID
Hospira Inc	palonosetron hydrochloride	0409-2503	MANNITOL

What are the Most Frequently-Used Excipients in PALONOSETRON HYDROCHLORIDE?

# Of NDCs	Excipient
16	CITRIC ACID MONOHYDRATE
17	EDETATE DISODIUM
1	GLYCINE
15	HYDROCHLORIC ACID

Excipient Strategy and Commercial Opportunities for Palonosetron Hydrochloride

Last updated: February 26, 2026

What is the role of excipient strategy in the formulation of Palonosetron Hydrochloride?

Excipients support stability, manufacturability, and patient compliance of Palonosetron Hydrochloride formulations, particularly in injectable or oral forms. The choice of excipients impacts drug release, bioavailability, shelf-life, and tolerability.

What excipients are typically used in Palonosetron Hydrochloride formulations?

The formulation depends on the dosage form:

Injectable Formulation

• Buffer agents: Phosphate buffers maintain pH stability.
• Preservatives: Methylparaben to prevent microbial growth.
• Solubilizers: Polysorbates or cyclodextrins to enhance solubility.
• Antioxidants: Ascorbic acid to prevent oxidation.

Oral Formulation

• Fillers: Lactose, microcrystalline cellulose for bulk.
• Disintegrants: Croscarmellose sodium to facilitate dissolution.
• Binders: Povidone to ensure tablet integrity.
• Lubricants: Magnesium stearate for manufacturing process.

How does excipient selection influence manufacturing and commercial viability?

Optimized excipient choices reduce manufacturing costs and enhance formulation stability. For instance, selecting cost-effective fillers minimizes expenses, while stabilizers improve shelf life, extending product marketability.

What are the market trends related to excipient innovations for Palonosetron Hydrochloride?

Emerging trends include the use of:

• Biodegradable excipients: Reduce environmental impact.
• Modified-release excipients: Enable sustained or targeted delivery.
• Co-processed excipients: Simplify manufacturing processes and improve performance.

These innovations are gaining traction in generic and branded formulations, expanding market options.

What are the commercial opportunities linked to excipient strategies?

1. Formulation differentiation: Tailoring excipients enhances bioavailability or reduces side effects, offering competitive advantages.
2. Intellectual property: Patenting unique excipient combinations or delivery systems creates licensing opportunities.
3. Cost reduction: Developing lean excipient profiles lowers production expenses.
4. Regulatory advantages: Using excipients with established safety profiles expedites approval.
5. Global market access: Local sourcing of excipients can address regional supply chain constraints.

How can companies leverage excipient strategy for Palonosetron Hydrochloride?

• Invest in R&D to identify stable, cost-effective excipients.
• Explore co-processing to develop novel delivery systems.
• Build partnerships with excipient manufacturers for custom formulations.
• Use excipient innovation to extend patent life via formulation patents.
• Stay updated on regulatory changes affecting excipient approval and use.

Market sizing and competitive landscape

The global antiemetic drugs market, including Palonosetron Hydrochloride, was valued at USD 2.6 billion in 2021 and projected to grow at a CAGR of 5% over the next five years (source [1]). Excipient choices influence manufacturing costs, pricing strategies, and regulatory pathways, directly impacting margins.

Conclusion

Strategic excipient selection enhances Palonosetron Hydrochloride’s stability, manufacturability, and patient compliance. Innovations in excipient technology underpin commercial opportunities in product differentiation, cost savings, and regulatory advantage.

---

Key Takeaways

• Excipient selection is critical to formulation stability, manufacturing efficiency, and patient acceptance.
• Trends favor biodegradable, modified-release, and co-processed excipients.
• Formulation innovations open licensing and patenting opportunities.
• Cost-effectiveness and regulatory compliance drive excipient decisions.
• Market growth supports expansion through differentiated formulations.

---

FAQs

Q1: How does excipient choice affect the shelf life of Palonosetron Hydrochloride?
A1: Proper selection of antioxidants, stabilizers, and buffering agents prevents degradation, extending shelf life.

Q2: What regulatory considerations exist for excipient use?
A2: Excipients must have established safety profiles, be approved by relevant agencies (FDA, EMA), and meet pharmacopeial standards.

Q3: Can novel excipients serve as a competitive advantage?
A3: Yes; they can enable unique delivery profiles, improve stability, and provide patent protection.

Q4: How do co-processed excipients benefit manufacturing?
A4: They simplify formulation processes, reduce excipient quantities, and improve batch-to-batch consistency.

Q5: What is the importance of regional sourcing in excipient strategy?
A5: Local sourcing can reduce supply chain risks, lower costs, and facilitate regional regulatory approvals.

---

References

1. MarketsandMarkets. (2022). Anti-Emetics Market by Drug Class, Application, and Region: Global Forecast to 2027.